Asthma Inhaler Cost in India: What Sets the Price
What asthma inhalers actually cost in India, why NPPA caps some formulations and not others, and how generic and Jan Aushadhi options change the bill.
Per-dose pricing understates the real comparison because inhalers are sold as multi-dose devices, typically 60 or 120 doses per canister, and brand, device type and pharmacy markup all sit on top of the regulated per-dose ceiling. This piece breaks down what NPPA actually controls, what it doesn't, and where a cheaper generic or Jan Aushadhi option changes the asthma inhaler cost picture.
What does NPPA actually control on inhaler pricing?
NPPA fixes ceiling prices for scheduled formulations listed in Schedule I of the Drugs (Prices Control) Order 2013, and budesonide-formoterol combinations at specific strengths are among the respiratory formulations scheduled under this order. A manufacturer cannot legally sell above the NPPA ceiling price for a scheduled strength and pack size.
Not every inhaler formulation, device type or brand sits under an active schedule entry, and unscheduled formulations are free to price at whatever the manufacturer sets, subject only to the general DPCO cap limiting annual price increases. This is why two inhalers delivering a similar drug combination can carry meaningfully different shelf prices depending on their schedule status.
Why do device type and delivery mechanism change the price?
A dry powder inhaler and a metered-dose inhaler delivering the same drug combination at the same strength are priced differently under NPPA's own schedule, with DPI formulations generally carrying a higher ceiling than MDI formulations for an equivalent strength. This reflects the different manufacturing cost of the device itself, not the drug.
Device-specific pricing, such as NPPA's separate approval of pricing for a proprietary breath-actuated inhaler device, shows that the delivery mechanism is priced as a distinct cost component from the active drug. A prescriber's choice between device types therefore has a direct cost consequence for the patient, separate from which molecule is chosen.
Does a generic inhaler cost less than a branded one for the same molecule?
Yes, generally, for the same reason generic pricing works across other drug categories: lower marketing spend on a generic version translates to a lower retail price for a chemically equivalent product. Since NPPA sets only a ceiling, not a floor, a generic manufacturer of a scheduled inhaler formulation can price below the ceiling while a heavily marketed brand often prices at or near it.
This gap matters specifically for a chronic, refill-heavy condition like asthma, where a patient buying the same combination every month accumulates the price difference across a full year of therapy rather than a single purchase.
Does Jan Aushadhi stock asthma inhalers, and at what price band?
The Pradhan Mantri Bhartiya Janaushadhi Pariyojana's product basket has grown to roughly 1,800 medicines and 285 surgical items, sold at 50–90% below open-market prices for equivalent branded products, per the scheme's own reporting. Respiratory formulations, including inhaled bronchodilators and steroids, sit within this broader generic basket, though availability at a specific Jan Aushadhi Kendra depends on that outlet's stock on a given day.
For a chronic respiratory patient managing cost over years rather than one prescription, the scheme's discount band is large enough to materially change adherence economics, provided the specific formulation and strength a prescriber has chosen is actually in stock at the nearest Kendra.
How much does asthma inhaler cost vary across a year of regular use?
A patient on a maintenance combination inhaler typically needs a refill roughly every one to two months depending on dose and inhaler technique, which means a device priced even a few rupees higher per dose compounds into a meaningfully larger annual cost across 6–12 refills. This is the practical reason device type, schedule status and brand choice matter more for asthma inhaler cost than for a one-time-purchase medicine.
Rescue inhalers used only during symptomatic episodes follow a different usage pattern, purchased less predictably and often replaced before the canister is fully used, which changes the annual cost calculation from the maintenance-inhaler math above.
What does this mean for a hospital's in-house pharmacy stocking decision?
Asthma and COPD patients are among the most reliably recurring prescriptions a hospital respiratory or general medicine OPD writes, and an inhaler is a device-specific product that a patient generally cannot substitute mid-therapy without a prescriber's involvement. If the in-house pharmacy doesn't stock the specific device and strength a doctor has prescribed, that patient walks to an outside chemist for every single refill going forward, not just the first one.
That is a durable, multi-year revenue loss on a single chronic patient, not a one-time miss. Medyzen's managed hospital pharmacy services piece covers how a managed pharmacy model is built to hold recurring-refill stock like this reliably, and the prescription leakage piece covers what that ongoing leakage costs a hospital across a full patient panel. Our asthma inhaler names guide covers the specific molecules and combinations in more clinical detail.
Sources
- 1NPPA Updated Price List as on 15/05/2024 — Directorate of Drugs Control, Government of Kerala, reproducing National Pharmaceutical Pricing Authority ceiling prices under DPCO 2013
- 2NPPA monitors the prices of scheduled and non-scheduled medicines under DPCO, 2013 — Press Information Bureau, Government of India
- 3National Pharmaceutical Pricing Authority — official notifications — Ministry of Chemicals and Fertilizers, Government of India
- 4Pradhan Mantri Bhartiya Janaushadhi Pariyojana — product basket expansion — All India Radio News, Government of India
- 5Pradhan Mantri Bhartiya Janaushadhi Pariyojana — Department of Pharmaceuticals, Government of India
This article is for informational purposes and is not a substitute for professional medical advice. Price figures are drawn from cited NPPA and government sources current as of the date checked and are subject to periodic revision. Consult a treating physician for individual prescribing decisions.
FAQ
Frequently asked questions
No. Only formulations and strengths listed in Schedule I of the DPCO 2013 carry an NPPA ceiling price. Unscheduled formulations, devices and brands price freely, subject only to the general annual increase cap.
NPPA's own schedule sets different ceiling prices for DPI and MDI formulations of the same drug combination and strength, reflecting the different device manufacturing cost rather than a difference in the drug itself.
The scheme's product basket, which includes respiratory formulations, is priced 50–90% below open-market equivalents on average, though availability of a specific formulation depends on Kendra-level stock on a given day.
A generic version of an NPPA-scheduled formulation must meet the same regulatory quality and bioequivalence standards as the branded product; the price difference reflects marketing spend, not a difference in the approved drug itself.
Asthma is typically managed with a maintenance inhaler refilled every one to two months, so a small per-device price difference compounds into a significant annual cost difference across repeated refills.
Dr. Priya MenonMBBS, MD (General Medicine)
Consultant Physician (Internal Medicine)
Dr. Priya Menon is a consultant physician in internal medicine, writing on drug classes, side-effect profiles, and evidence-based clinical use for hospital and prescriber audiences.